Sangamo Therapeutics (NASDAQ:SGMO) Releases Earnings Results, Misses Expectations By $0.03 EPS

Sangamo Therapeutics (NASDAQ:SGMO) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03), Zacks reports. The company had revenue of $6.44 million for the quarter, compared to analysts’ expectations of $7.90 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock opened at $0.44 on Thursday. The firm has a market cap of $100.39 million, a PE ratio of -0.58 and a beta of 1.46. The firm’s 50 day moving average price is $0.75 and its two-hundred day moving average price is $1.34. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18.

Analysts Set New Price Targets

Several equities analysts have issued reports on SGMO shares. Truist Financial decreased their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Royal Bank of Canada reiterated a “sector perform” rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Barclays reduced their price objective on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Sangamo Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $4.50.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.